ANDA 87510, held by Parkedale Pharmaceuticals. Procainamide Hydrochloride.
As of Nov 21, 2026, ANDA 87510 (Procan SR), held by Parkedale Pharmaceuticals, was first approved by FDA on Sep 22, 1995, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 22, 1995 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Procan SR750MG · tablet, extended release;oral | Procainamide Hydrochloride | DiscontinuedReference drug |
| May 30, 1996 | Supplement 29Labeling | Approved | None posted |
| Sep 22, 1995 | Original application | Approved | None posted |
| Jun 23, 1993 | Supplement 26Labeling | Approved | None posted |
| Mar 3, 1992 | Supplement 25Labeling | Approved | None posted |
| Jun 6, 1991 | Supplement 24Labeling | Approved | None posted |
| Jan 27, 1989 | Supplement 20Labeling | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters